Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued (2017 - 2025)

Historic Shares Issued for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $3.1 million.

  • Crinetics Pharmaceuticals' Shares Issued fell 9359.36% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $539.0 million, marking a year-over-year increase of 1662.25%. This contributed to the annual value of $970.0 million for FY2024, which is 16287.21% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Shares Issued of $3.1 million as of Q3 2025, which was down 9359.36% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Shares Issued registered a high of $528.6 million during Q4 2024, and its lowest value of -$42000.0 during Q2 2021.
  • Its 5-year average for Shares Issued is $76.3 million, with a median of $3.1 million in 2025.
  • Examining YoY changes over the last 5 years, Crinetics Pharmaceuticals' Shares Issued showed a top increase of 27504047.62% in 2022 and a maximum decrease of 10008.68% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Shares Issued (Quarter) stood at $162.0 million in 2021, then plummeted by 100.01% to -$13000.0 in 2022, then soared by 221269.23% to $28.8 million in 2023, then skyrocketed by 1738.31% to $528.6 million in 2024, then tumbled by 99.42% to $3.1 million in 2025.
  • Its Shares Issued was $3.1 million in Q3 2025, compared to $2.9 million in Q2 2025 and $4.4 million in Q1 2025.